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In this review, we examine senescent cells and the overlap between the direct biological
impact of senescence and the indirect impact senescence has via its effects on other cell
types, particularly the macrophage. The canonical roles of macrophages in cell clearance
and in other physiological functions are discussed with reference to their functions in
diseases of the kidney and other organs. We also explore the translational potential of
different approaches based around the macrophage in future interventions to target
senescent cells, with the goal of preventing or reversing pathologies driven or contributed
to in part by senescent cell load in vivo.
Keywords: macrophage, senescence, ageing, fibrosis, immunoageing, immunevasion, senolytic, senescence-
associated secretory phenotypeINTRODUCTION
Ageing in humans is marked by a decrease in fitness over time with a simultaneous increase in
mortality (1). With increasing age, the functions of key biological systems begin to decline, as shown
by decreased nutrient sensing, stem cell exhaustion and cellular senescence (1). Due to advances in
healthcare, human life expectancy has increased worldwide, with estimates of the average global
population placing 1 in 9 people over 60, which is expected to rise to 1 in 5 by 2050 (2). As we age,
the incidence of physiological dysfunction increases as well, and thus the risk of age-associated
diseases such as chronic kidney disease (CKD), cardiovascular disease and type II diabetes (3) also
increases. These diseases predispose individuals to developing additional pathologies and increase
both morbidity and mortality. This calls for polypharmaceutical treatments and interventions to
maintain quality of life (2), which come with the caveats of side-effects and cross-reactions and are
therefore potentially detrimental to patient welfare. Because of these drawbacks, novel treatments
need to be developed to target the causes of these co-morbidities to reduce the need for large
amounts of medication.
This review aims to summarize the current understanding of the functions of senescent cells and
macrophages, and their combined effect on fibrosis within tissues. Focus will be given to the kidney,
supplemented by other relevant organ systems. Finally, we will summarize the challenges for future
research, and potential avenues for translating research studies into therapeutic advances.org June 2021 | Volume 12 | Article 7007901
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The trans-NIH Geroscience Interest Group (GSIG) held a
summit in 2016, focusing on the seven pillars of ageing,
expanding on previously assessed hallmarks (1). These seven
factors include metabolic changes, macromolecular damage,
epigenetic changes, inflammation, adaptation to stress, stem
cells and regeneration and changes to proteostasis (4), all of
which share interconnected relationships (Figure 1).
Ageing is associated with progressive decline in function of
multiple organ systems. Bone loss has long been associated with
advancing age, with a reduced capacity to heal fractures (5),
which is marked by a decrease in osteocytes with increasing age
(6). The consequences of this are seen in the increase of non-
traumatic bone fractures, with the frequency of these fractures
increasing for persons aged over 60 (5).
Cardiovascular function is negatively impacted by age, as the
arterial tree can thicken and stiffen (7). This trend, seen in both
genders, and as measured by carotid-femoral pulse wave velocity
(PWV), diverges at age 50 for men and women, with men having
a steeper increase of PWV (7). This has key implications for
certain diseases such as end-stage renal disease, as significantly
higher ‘pulse-wave velocity’ (PWV) has been used to predict
mortality in patients (8). This indicates certain aspects of ageing
differ based on gender, suggesting a hormonal role contributes to
the phenotype, however this is beyond the focus of this review
and will not be discussed.
Chronic kidney disease (CKD) is relevant in ageing studies as
it has been found that there are signs of premature ageing in
CKD patients such as osteoporosis, poor wound healing and
inflammation, leading to the proposal that CKD be included as a
disease that displays traits usually associated with advanced
ageing (9). The aged kidney is marked by up to 40% less renal
blood flow in old vs. young male patients (10). Increasing donorFrontiers in Immunology | www.frontiersin.org 2age is associated with reduced transplant function after donation,
even in the context of well-preserved pre-donation function (11).
Overcoming these problems requires investigating the links
between ageing and physiological dysfunction, which is the
greatest risk factor for the diseases listed previously.
Ageing is associated with decline in cellular functions,
including the phagocytic clearance of cells. This has been shown
using in vitro mouse models in which serum from aged mice (24
months old) was added to cultures of macrophages, which resulted
in decreased levels of phagocytosis (12). In addition to this, direct
studies of clearance of apoptotic skin cells (induced by UV B
irradiation) showed a higher level of apoptotic keratinocytes
compared to younger mice indicating reduced phagocytic
activity. Of note, in aged mice with reduced phagocytosis of
apoptotic cells, renal autoantibodies developed along with
complement deposition within the kidney, findings consistent
with the development of autoimmunity (12). Macrophage
numbers were not significantly reduced or increased in older
mice compared to younger mice in these studies and therefore, a
decrease of macrophage phagocytic activity is implicated. This
shows that the persistence of apoptotic cells has a detrimental
effect on normal tissue function, particularly the kidney (13).
However, when macrophage phagocytosis was assessed in vitro,
there was no difference between young and old derived, indicating
systemic factors may modulate the potency of macrophage
phagocytosis (13).
‘Gerontology’ focuses on ageing and older adults, whereas
‘geroscience’ emphasizes the overlap of normal ageing and
chronic disease. The geroscience hypothesis predicts that the
targeting of the suspected drivers of ageing will also mitigate the
main risk factors of multiple chronic diseases (4). This would
have the potential to increase the health span of individuals.
An example of this is caloric restriction (CR), and has long
been known to have pro-longevity properties as first seen inFIGURE 1 | The seven pillars of ageing proposed by Kennedy et al. (4). Key aspects in this review focus on the adaptation to stressful environments in the form of
senescence and macrophages, and the inflammatory effect it can have on its surroundings. Annotations to each pillar highlight possible contributions to direct
senescence or producing a senescence-promoting environment.June 2021 | Volume 12 | Article 700790
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which showed an increase in longevity, decreased cancer incidence
and a rejuvenated immune system through intermittent fasting
(15). Data for controlled calorie consumption in humans showed a
limited impact from calorie restriction (16). However, a meta-
analysis of clinical studies indicated increases of fibrinolytic
activity, to degrade fibrin deposits, improving prognosis for
cardiovascular disease patients (17). This indicates at least
partial benefits when applied to humans. However, this may
come at a cost, as recent studies in grey mouse lemurs
(Microcebus murinus) indicated that moderate caloric restriction
(30%), accelerated grey matter atrophy (18). Despite this, lifespan
was increased (50% median increase), with a decrease in nephritis
as cause of death and cognitive function comparable to controls.
Further studies are warranted to make comparisons to humans
who have higher-level reasoning capacities that may not be
properly assessed with animal models.SENESCENCE
Senescence involves irreversible arrest of the cell cycle (19) and
was first observed by Hayflick and Moorhead (20). Multiple
factors can stimulate senescence in a cell, including DNA
damage, chronological ageing in the form of telomere
shortening and cell stress from chronic conditions (19, 21, 22).
This is marked by increased expression of cyclin dependent
kinase inhibitors p21CIP1 and p16INK4a (23, 24) that drive cell-
cycle arrest. Despite the impact of external stress, senescent cells
remain metabolically active with an altered secretome of
cytokines, chemokines and proteases that have the capacity to
modulate the activity and functionality of surrounding cells. This
is called the senescence-associated secretory phenotype (SASP)
(25). These include, but are not limited to, interleukin-8 (IL-8)
(26), TNF-a (27), IL-6 (28) and IL-1a (29). Alone, none of these
markers are definitive for senescence. Combinations of other
markers such as senescence-associated b galactosidase (SA-b-
Gal), a marker of increased lysosomal activity, gH2AX which is a
marker of double DNA strand breaks and the DNA damage
response, along with markers for cell-cycle checkpoints (p21CIP1,
p16INK4a) (30) are used to infer senescence of cells.
Acute vs Chronic Senescence
Acute senescence is a tightly regulated process seen during
wound healing (31, 32), in embryogenesis (33, 34), and in
protection from cancer (35). Wound healing is a tightly
regulated process of inflammation, infi ltration, and
proliferation, with specific proteins driving senescence of
particular cells. The CCN1/CYR61 matricellular protein, is
involved in this process and can induce senescence in the
fibroblasts at site of wound repair (32). Mouse studies in which
the CCN1 locus was replaced a mutated sequence showed that
mice lacking the active form of this gene had faster wound
healing but greater levels of fibrosis (scarring) and lower levels of
senescence markers including SA-b-Gal and p16INK4a (32)
compared to WT. As the exogenous addition of CCN1 toFrontiers in Immunology | www.frontiersin.org 3cutaneous wounds of mutated mice resulted in the increase of
Mmp2 , Mmp3 , and Mmp9 , and reduced expression
of Col1a1 and Tgfb1 (32), this indicates a role of senescence in
limiting excessive fibrosis in wound healing, where fibrosis could
become detrimental. The beneficial role of senescence in acute
wound healing is supported by studies using genetically-
mediated depletion of senescent cells - where senescent cell
removal resulted in a delay in skin wound closure (31).
Chronic senescence is marked by senescent cells that
accumulate with age and chronic diseases, such as pre-cirrhotic
fibrosis of livers (36, 37) and chronic kidney disease in which
senescent cell accumulation correlates to increased disease
severity (38) Accumulation of senescent cells also contributes
to radiation toxicity from radiotherapy (39, 40) and
chemotherapy (39). It is believed that chronically senescent
cells become problematic when they are not destroyed and
cleared by immune cells, such natural killer (NK) cells and
macrophages (41), and continue to generate signaling
molecules that systemically and locally affect the normal
function of cell (19).
Senescent cells that accumulate with age, and their associated
SASP, can alter the functions of other cells of an organism (42–
44). This ties in closely with the geroscience hypothesis (4). If
ageing is viewed as a disease, certain drivers have been identified.
For example, the expression of p16INK4a has both short and long
term impacts, as it prevents cancer by triggering senescence, the
cost of which is that ageing is promoted (45). Selective p16INK4a
ablation ameliorates some ageing phenotypes, increasing
production of T-cells and increases antigen-specific immune
responses, but causes an increased risk of cancers such as high-
grade B-cell neoplasms (45). Defense against cancer initiation is
one of the key roles of senescence, with oncogenes such as RAF
or BRAF causing oncogene-induced senescence (35). The
advantage of senescence in this case would be the continued
survival of an organism with gradual decline from ageing versus
the more imminent death of the organism due to increase in
cancer incidence, an example of antagonistic pleiotropy. This
highlights the need for senescence as a protection mechanism,
but a need to remove senescent cells after they have fulfilled their
protective role, to prevent the detrimental impact of exposure of
the SASP to healthy tissues and organs.SENESCENCE IN THE KIDNEY
Senescence With Age/Injury
When the kidney undergoes damage, the resident cells including
renal tubular epithelial cells, endothelial cells, podocytes, T-cells
(46) and macrophages (47) produce paracrine signaling factors
that affect resident tissues, termed the chronic kidney disease
(CKD)-associated secretory phenotype (CASP) (48). The
parallels between the CASP and the commonly accepted SASP
may be due to the presence of senescent cells within the
dysfunctional kidney, as many cytokines of the SASP are also
found in the CASP such as IL-8, TNF-a and IL-6 (48). This
would suggest that any comparisons of the secretory phenotypesJune 2021 | Volume 12 | Article 700790
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types of the renal system as this may reveal other cell targets for
therapeutics. This would help determine if SASP is driving the
cell behaviors in the tissue or if they are independent.
Age has been shown to be a key contributor to progression of
acute kidney injury (AKI) into chronic kidney disease (CKD) due
to an inability to fully recover from an acute insult (49–51). Age
can also be detrimental to transplantations, including kidneys, in
which mice deficient in p16INK4a displayed fewer senescent cells,
with an increase in proliferative rates of tubular cells, all leading
to significantly better survival of donor mice (52). Studies using
bilateral renal ischemia-reperfusion to induce AKI in young (8-
10 weeks) and ageing (46-49 weeks) mice showed an increase in
fibrosis by picrosirius red staining and immunolocalization of
cellular fibronectin, collagen III and collagen IV in the older mice
(49). This correlates to higher levels of p53 and p21CIP1
expression as well as SA-b-Gal staining in the older mice. Less
fibrosis and tubular atrophy was seen in p16INK4a knock-out
mice after ischemia-reperfusion injury (52) and in addition to
this, the deletion of senescent cells in old (18 – 24 months) and
prematurely aged mice, resulted in a better prognosis (53).
Whilst activation and proliferation of fibroblasts can be a key
wound-healing response to injury, excessive fibrosis can also be
detrimental to physiological functions across multiple organs
including the heart, kidney, and liver.
Senescence in Other Organs
Liver pathologies can also be made worse by the presence of
senescent cells as has been reviewed (54). Chronic injuries in the
liver can lead to fibrosis, and may develop into cirrhosis, but may
be resolved by several endogenous mechanisms, one of which is
the CCN1 protein which induces senescence of hepatic
myofibroblasts (55). However, this has also been shown to
activate DNA damage response (DDR) pathways and p53 by
engaging integrin a6b1 which generates the production of
reactive oxygen species (ROS) which stimulates the DDR,
activating the p53-p21CIP1 dependent pathway of cellular
senescence (32, 55, 56). These acutely senescent cells display
anti-fibrotic transcriptional programs, resolving potentially
dangerous fibrosis of the liver (55). This also demonstrates the
complex and contextually significant role of senescent cells in the
body, which can be beneficial in injury resolution and wound
healing, and must be taken into consideration with any systemic
therapies that target senescent cells.
Senescent cells are found in multiple tissues of the body,
including the bones and brain. For example, an increase in the
number of senescent astrocytes are found in cadaveric
Parkinson’s disease patients compared to normal control
tissues, along with an increase in SASP markers IL-6, IL-1a
and IL-8 (29). In mice, clearance of senescent [glial] cells of the
brain has been shown to reduce the accumulation of
hyperphosphorylated tau aggregates in the dentate gyrus
(responsible for memory formation and cognition), that has
been linked to cognitive decline (57) and Alzheimer’s (58).
Similarly, clearance of senescent cells that accumulate in
osteoarthritis produced a pro-regenerative environment as
marked by subchondral sclerosis and osteophyte formationFrontiers in Immunology | www.frontiersin.org 4similar to controls (59). Inhibition of SASP factors generated
by senescent cells, such as the profibrotic TGF-b, has also been
shown to improve regeneration in the liver (60).CLEARANCE OF SENESCENT CELLS BY
THE IMMUNE SYSTEM
When senescence is induced, these cells need to be cleared from
tissues to prevent damage to the surrounding cells. The SASP
generated by senescent cells is able to promote immune clearance
of the senescent cells (61). The SASP potency can be modulated by
the epigenetic regulator BRD4 (Bromodomain-containing protein
4), as when this was knocked down, secreted SASP factors in in
vitro cultures were reduced (62). In vitro experiments also showed
that conditioned medium from senescent cell cultures induced
senescence in naïve cells, halting proliferation and upregulating
SA-b-Gal activity, whereas conditioned medium from BRD4-
inhibited cultures had significantly reduced capacity to transmit
senescence to naïve cells (62).
Senescent cell destruction within tissues can be carried out by
natural killer (NK cells). One of the first instances in which this
was reported was in a study in which p53 was activated in liver
carcinomas using RNAi, resulting in rapid tumor regression, and
inhibition of NK cells showing significantly delayed tumor
regression compared to controls (63, 64). By Day 8 of p53
senescence induction, infiltration of leukocytes including NK
cells was observed in mouse kidneys by immunohistochemistry,
with detection of NK-specific transcripts (Klrb1 and Klrd1)
upregulated in tumors suggesting NK infiltration because of
the presence of senescent tumor cells (63).
NK cells are not the only immune cell involved in the
clearance of senescent cells. Macrophages can be recruited by
numerous factors, including SASP factors and the secretome of
NK cells. NK cells can produce interferon gamma (IFN-g) upon
interaction with senescent cells (65) which acts to recruit
macrophages (66). In addition to this the induction of tumor
senescence can lead to an increase in oxidative stress, as shown in
breast cancer due to protein acetyltransferase dysregulation (67).
This led to an increase in chemoattractants CCL2, CXCL1,
CXCL16 and IL-8, which recruit NK cells and macrophages,
causing clearance of senescent tumors (67). This is matched in
other organs; for example the liver where senescent hepatic
myofibroblasts, produce CCL2, attracting CCR2+ macrophages
to the liver to clear pre-cancerous cells, demonstrating a
protective role for senescence in the liver (68). Together this
shows the orchestration of immune cells by signaling of
senescent cells to exert a protective anti-cancerous role, with
the roles of macrophages in senescence being explored later.MACROPHAGES
Functions
Macrophages have a diverse range of functions, including tissue
homeostasis, immune surveillance, resolving cutaneous woundJune 2021 | Volume 12 | Article 700790
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supporting embryogenesis (72). One of their primary functions
as ‘big eaters’ is to phagocytose cells, such as apoptotic cells
[efferocytosis (73)] and senescent cells (33). One component of
the macrophage lysosome is DNase II which degrades the DNA
of engulfed cells (74). Mouse experiments in which DNase II was
knocked out, showed undigested DNA within the lysosomal
compartment of macrophages, leading to activation of the
immune system as marked by increases in IFN-g and more
moderately, TNF-a (74). This indicates that incomplete
phagocytosis can be pro-inflammatory. During inflammation
of the body, macrophages can be recruited by chemotactic
factors secreted by neutrophils to aid in inflammation
resolution. This is useful in host defense against pathogens in
which macrophages phagocytose apoptotic neutrophils (75)
which promotes inflammation resolution (76).
The ability of macrophages to robustly clear senescent cells
from the tissues of the body diminishes with age (77). One
proposed explanation for this is for macrophages to be able to
acquire senescent-like properties, termed “senescent associated
macrophages (SAMs)”. A possible cause of this may be due to the
ability of the SASP of senescent cells to induce senescent features
in macrophages such as SA-b-Gal positivity (28, 78). However, as
there is inherent b-galactosidase activity in macrophages due to
their lysosomes (79), this cannot be an accurate marker to
definitively class macrophages as senescent.
Macrophages in the Kidney and Models
to Dissect Senescent Cell–Macrophage
Interactions
Resident macrophages of the kidney arise from three separate
sources, the C-Myb independent yolk-sac EMP-derived, fetal
liver C-Myb dependent EMP-derived and finally, hematopoietic
stem cells (HSC) as comprehensively summarized (80).
Macrophages in the adult kidney can be separated by markers
into distinct populations, which may result in them displaying
differing responses to stimuli.
Circulating monocytes can populate the kidney and mature to
macrophages to continue to provide immune and injury
response, but these are not precise analogues to the long-lived
kidney resident macrophages (KRM) (81). Models have been
developed to study the effect of senescent cells in the kidneys of
young mice (82). These models utilize Pax8 which is a
transcription factor involved in the formation of the kidney
tissues in mice, with human homologues (83). Conditional
excision of mdm2 is driven by Pax8; mdm2 codes for MDM2
which negatively regulates p53, promoting stabilization and
degradation by ubiquitination, promoting senescence induction
(84). The Csf1rDFIRE/DFIRE (FIRE) mouse has recently been
developed, and shows robust elimination of resident F4/80high
macrophages in multiple tissues of interest including the kidney
(85). This was achieved by the removing the super enhancer
(fms-intronic regulatory element) located in the second intron of
the Csf1r gene (85). This improves on the limitations of the
Csfr1-/-macrophage deficient mouse model which showed lack of
bone remodeling (osteopetrosis), resulting in deformities duringFrontiers in Immunology | www.frontiersin.org 5development, and reproductive defects, resulting in lower
pregnancy rates (86). In addition to this, the niche population
is not repopulated by circulating monocytes (85), which suggest
the alteration of the niche-cell interaction by the removal of the
CSF-1 receptor from F4/80+ cells (85).
These models will provide information of the effects of
senescent cells in young animals and their effects on
macrophages in an in vivo setting. These two models may
provide insight into how different macrophage populations
interact with senescent cells of the kidney, for instance in the
absence of resident F4/80high renal macrophages, and in mice
exposed to chronically senescent cells from an early age.MACROPHAGE PLASTICITY
Macrophages display phenotypes adapted to their various roles
and can be classified very simply as M1 (pro-inflammatory) or
M2 (pro-regenerative) states based upon cell surface markers,
synthesis of specific factors and biological activities. This was first
suggested by Mills and colleagues, based upon the Th1/Th2
paradigm (87) and represents extremes of a spectrum of
polarization states (88) (Figure 2). M1 macrophages generate
inflammatory cytokines (89) in response to microbial infection
or inflammation, such as IL-6 (90), nitric oxide (NO) (91, 92),
TNF-a, IL-1b, IL-12 and IL-23 (93, 94). Inflammatory
monocytes are recruited to sites of acute and chronic kidney
injury, with the SASP-associated CCL2 promoting the
accumulation of cytotoxic and pro-inflammatory M1
(classically activated) macrophages (95, 96).
After injury, pro-reparative or ‘alternatively activated’ M2
macrophages can be induced by exposure to Th2 type cytokines,
such as IL-4 and IL-13 (97, 98) or phagocytosis of apoptotic cells,
with transition from M1 to M2 polarization seen in successful
resolution of inflammation by the production of mitogenic and
pro-survival signals that promote renal repair (88, 99, 100).
Failure of macrophages to switch from a pro-inflammatory
state to the pro-reparative state has been implicated in chronic
diseases, including chronic kidney disease due to the excessive
fibrosis caused by the presence of a proinflammatory
environment (49). M2 macrophages have anti-inflammatory
roles, secreting cytokines such as IL-10, and express markers
such as CD206, Ym1, CD163, CCL1, CCL18, FIZZ1, arginase1
(Arg1) and chitotriosidase genes (101–103). In the lungs it has
been shown that M2 macrophages are able to suppress
inflammation secretion of factors that affect the behavior of
surrounding cells (103).
M2 macrophages are crucial to wound healing, with their
functions including clearance of debris, activation of regulatory
T-Cells, suppression of inflammation, reduction of neutrophil
infiltration and antagonism of M1 macrophage functions (104).
M2 macrophages can be further subdivided into M2a,b,c and d
types (Figure 2), with M2a being the most commonly described
and referred to as alternatively activated (IL-4 induced) (100).
M2a are activated by IL-4 and IL-13 while M2c are activated by
IL-10 and TGF-b, and glucocorticoids (105). M2a (wound-June 2021 | Volume 12 | Article 700790
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like growth factor (IGF) and fibronectin (106). M2c potently
induce regulatory T-cells, which aid in protection from renal
injury (104, 107). It has been shown, using mouse renal models,
that both M2a and M2c polarizations can be robustly induced in
aged mononuclear cells in vitro, whereas polarization was limited
in vivo in IRI models when compared to young mice (108). This
suggests that the intrarenal microenvironment of aged mice after
IRI has a greater negative impact on macrophage polarization
than the ageing of the bone-marrow derived monocytes (108).
M2c subtypes also have strong anti-inflammatory and pro-
fibrotic functions due to the production of IL-10 and TGF-b,
respectively, with high expression of Mer receptor tyrosine
kinase (MerTK) for efficient phagocytosis of apoptotic cells
(104, 106). M2b (regulatory macrophages) are activated by IL-
1, LPS (105) and secrete both pro-inflammatory factors (IL-1b,
IL-6, and TNF-a) as well as the potent anti-inflammatory IL-10,
due to their roles in the regulation of inflammation and immune
response (88, 106). M2d (tumor-associated macrophages –
TAMs) are activated by IL-6 and A2 adenosine receptor (AR)
agonists (105, 106), and represent a more detrimental class of M2
macrophage as they contribute to angiogenesis (by release of
vascular endothelial growth factor – VEGF) and cancer
metastasis (109, 110).
As with M1 macrophages, niche context can also influence
M2 functions, as increased fibrosis (collagen I, II and III
deposition) is seen in injured kidneys due to the signaling
effects of macrophages on resident kidney fibroblasts (111). To
some extent, macrophage origin can also affect polarization
capacity, as the M2a subtype derived from bone marrow wasFrontiers in Immunology | www.frontiersin.org 6more likely to switch to an inflammatory phenotype, than M2a
cells derived from the spleen (104). Macrophages are not
terminally differentiated and retain the ability to switch to
other phenotypes. As well as M1 macrophages having the
ability to switch to a more pro-repair phenotype (99), M2
macrophages can be induced to adopt proinflammatory
features to enable microbial killing (112).
Macrophages and Fibrosis
In the kidney, with increased ageing, fibrosis can be driven by the
upregulation of the Wnt/b-catenin signaling and renin-
angiotensin system (RAS) pathways, shown by an increase of
fibronectin and picrosirius red staining (113). This was validated
by the experimental overexpression of Klotho which acts as an
antagonist of Wnt/b-catenin, resulting in diminished renal
fibrosis, preservation of mitochondrial mass and reduced
production of reactive oxygen species (ROS) (113). Levels of
Klotho decrease with age in mice (over 12 months), correlating
to increase in fibrosis and aging markers. This indicates that
potent and selective inhibitors of the Wnt/b-catenin pathway
could provide a useful therapeutic for age-related fibrosis as well
as fibrosis caused by the presence of senescent cells due to injury
in the kidney.
However, fibrosis may be caused by other mechanisms, such as
macrophages. Pro-reparative (“M2”) macrophages have the
potential to accelerate tissue repair, but if they remain persistently
activated, or are continually recruited, they may contribute to
chronic fibrosis (114). This is due to secreted cytokines from
macrophages, such as TGF-b which simultaneously has anti-
inflammatory and profibrotic activity (114).A
B C
FIGURE 2 | The simplified polarizations of macrophages and potential interactions with senescent cells. (A) Macrophages can be in an unpolarized M0 state, and
polarize to the classical inflammatory M1 state, or the alternately activated, pro-reparative M2 state, with subcategories of M2 activation that dictates function, with
prominent drivers listed. (B) Plasticity of macrophages allows a shift in polarized states from M1 to M2 that can be inhibited by the secretosome of senescent cells
(SASP), associated with injuries to organs and increasing age. (C) Inhibition of polarization shift can be ameliorated with pharmaceutical compounds ultimately
minimizing the effect of the SASP. SC, Senescent cell; TAMs, Tumor Associated Macrophages.June 2021 | Volume 12 | Article 700790
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macrophages, which undergo changes in secretory production.
Importantly the anti-inflammatory IL-10 cytokine is decreased
(115). This has important implications for tissue function as IL-
10 is also anti-fibrotic by inhibition of pro-fibrotic molecules
such as TGF-b (116). Recent therapeutic research has focused on
the potential of utilizing IL-10 for its potent antifibrotic
properties (117). This highlights an important decline in a key
M2 macrophage signaling molecule, demonstrating a decrease in
potency with host age and leading to tissue environments more
permissive to fibrosis.
Macrophages in Kidney Injury
When the kidney is injured, proliferative monocytes are
recruited and infiltrate the kidney to the site of tissue damage
(118). This occurs after IRI (119) along an IL-6 chemotaxis (120),
among other signaling factors. Monocyte infiltration begins early
after injury, as shown by increased F4/80 staining at day 1. These
monocytes migrate towards injured tubules of the outer medulla
and mature to macrophages (121). Macrophages enhance pro-
inflammatory damage caused by injury, as depletion of
macrophages can be beneficial at early timepoints, as marked
by a decrease in in blood urea nitrogen (BUN). However, they are
also needed for resolution of inflammation and tissue repair, as
their depletion (by liposomal clodronate) is detrimental at later
(72 hour) timepoints at which recovery begins (13). This affect
appeared to be due to the inflammatory environment of the
kidney and how it changes over the first 72 hours of injury, in
which pro-inflammatory cytokines such as CCL2 were
upregulated in the first 24 hours, and anti-inflammatory IL-10
rose in later stages (13). This indicates that macrophages
involved in kidney injury have functions that are dependent on
the local cytokine signals, which affect their polarization, and
show a beneficial effect when depleted at early inflammatory
timepoints and a beneficial effect when re-administered at later
timepoints. Depletion of macrophages by clodronate liposomes
has been shown in other studies, delivering functional protection
and reduced acute tubular necrosis (122). Genetic diphtheria
toxin (DT)-mediated depletion of CD11b-DTR mouse
macrophages did not give a protective effect compared to
controls, possibly due to clodronate having a minimal effect on
resident CD11b+ populations (122). This suggests that partial
depletion of mononuclear phagocytes at earlier timepoints has a
cytoprotective effect.
After renal IRI, M2 macrophages are present at later
timepoints of injury repair (~day 3), coinciding with peak cell
division of tubular cells (121). Gene expression assays by qPCR
showed that macrophages (fluorescence associated cell sorted for
F4/80+) in the injured kidneys displayed a concurrent decrease of
iNOS and increase of Arg1, markers of pro-inflammatory/
classical and alternatively activated macrophages respectively
(121). To verify a transition of macrophage states from M1 to
M2, and not polarization of infiltrating monocytes, bone marrow
monocytes were labelled with PKH26 and exposed to interferon
gamma (Ifn-g) to stimulate iNOS-positive, pro-inflammatory
M1 polarization, and injected 3 days post-IRI. PKH26 labelled
cells collected at day 5 displayed downregulated iNOS expressionFrontiers in Immunology | www.frontiersin.org 7and increased CD206 (mannose receptor), a marker for M2
polarization, suggesting their polarization altered in response to
their environment (121).
Most of these studies have been carried out on young mice.
However, the presence of senescent cells can impact macrophage
phenotype. For instance, inhibition of the SASP cytokine TNF-a
in human macrophages derived from peripheral blood
mononuclear cells (PBMCs) induced a shift in polarization of
macrophages to an M2 phenotype from an M1 phenotype and
decreases the secretion of pro-inflammatory cytokines (TNF-a,
IL-6 and IL-12) (123). Further experiments showed an increase in
phagocytosis of M1 macrophages. Taken together, this indicates
that through SASP signaling, senescent cells can reduce phagocytic
activity of macrophages and inhibit the transition to pro-
reparative M2 macrophages, leading to a persistence of pro-
inflammatory M1 macrophages. How the presence of senescent
cells with ageing might affect the roles of macrophages in
inflammation and tissue repair after injury of the kidney and
other organs warrants further experimental investigation.SENESCENCE INDUCTION
IN MACROPHAGES
The concept of “macrophageing” was first introduced in 2000 (78,
124, 125) and suggests that macrophages are induced into
becoming senescent in response to signaling from surrounding
cells. This has been a controversial subject in previous years, as
although macrophages may display upregulation of senescence
associated markers such as p16INK4a and SA-b-Gal (126) they
remain proliferative indicating that they have not acquired “true”
senescence (127). Evidence indicates that these markers that
emerge are contextual in macrophages and may in fact be
indicative of their polarization (128). Recent research has
provided more evidence for senescent macrophages, as shown
by significant upregulation of both p16INK4a and p21CIP1 cell-cycle
checkpoints in a mouse model of DNA damage repair deficiency
(129). In addition to this, macrophages as sorted by F4/80+ and
CD11b+ markers showed significant upregulation of SASP
components, including TNF-a, IL-6 and IL-1b as compared to
littermates, in which the coding sequence for DNA repair protein
ERCC1 is not excised (129). This is matched by significant
increases in p16INK4a and p21CIP1 in the bone marrow
compartment of the transgenic mice, compared to 2 year old
wild-type control mice and un-induced controls, with an increase
in the pro-inflammatory IL-6 accompanying this. This field is
constantly being re-interpreted as new evidence is produced, and it
is beyond the scope of this review to advocate for or against
senescent macrophages, and will focus on the role(s) of senescent
cells upon macrophages and their ability to function.IMMUNOAGEING AND IMMUNEVASION
Ageing of the immune system is marked by a chronic level of
systemic inflammation, which contributes to the pathogenesis ofJune 2021 | Volume 12 | Article 700790
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seen in monocyte/macrophage populations of the body. The
peripheral blood monocytes that in some cases invade tissues
and supplement resident macrophages are reduced with age
(130). The macrophages of the lungs (alveolar macrophages)
have shown lower levels of phagocytosis of apoptotic neutrophils
(75). This can lead to increased susceptibility to infections such
as influenza, resulting in a higher mortality in mouse studies
(75). In the brain, phagocytosis of amyloid-beta is reduced in
multiple populations of blood monocytes (131).
The dysregulation of macrophage functions with age may be
linked to low levels of innate immune activation as marked by
sCD163 and CXCL10 (132). It was also found that age resulted in
higher levels of inflammation as shown by an increase in TNF-a
of aged monocytes compared to young human peripheral blood
monocytes (132). Higher levels of inflammation are also seen in
kidney macrophages of aged mice, with aged CD73+ kidney
mesenchymal stromal cells upregulating Ccl2 with a higher
proportion of CCR2+ macrophages detected (95). This
indicates an increase in pro-inflammatory macrophages with
age. This is made more detrimental by the presence of senescent
cells (Figure 2) that can cause macrophages to show ‘senescent
traits’ (78), losing potency as shown by the decrease of IL-10
synthesis by “M2”macrophages (115) and a significant reduction
in their capacity to phagocytose (133).
Macrophages of the spleen upregulate p16INK4a expression up
to 20-fold in response to ionizing radiation, which is in stark
contrast to the 4-fold upregulation seen in T-cells (134). This
indicates a higher sensitivity of macrophages to ionizing
radiation, as shown by a sharp decrease in absolute cell
number, which is rescued by targeted depletion of p16INK4a
cells. This would also indicate that immunosenescence induced
by the SASP of splenic cells partially models the decline of
immune system potency with age explained by inflammaging
(78) and demonstrated by a decrease in phagocytosis with age
(133). Given the key roles of macrophages in tissue repair, this
higher sensitivity to the SASP components could be an
explanation as to why senescent cell burden is such a
detrimental component of the ageing soma and the role of
decreased immune function has been shown to accelerate
senescent burden (135). Despite rescue of cell number by
p16INK4a cell depletion, phagocytic activity measured by uptake
of a fluorescent substrate, was diminished. It remains possible
that there exists a spectrum of senescence due to the multiple
components that can contribute to the phenotype, as senescence
markers such as p16INK4a, p21CIP1, and SASP components (IL-6,
IL-1a) can be present but well-established markers such as SA-b-
Gal can be absent (134).
CD47 is a membrane protein recognized as an inhibitory
signal of phagocytosis or a “don’t eat me” signal, first discovered
in mice injected with red blood cells from CD47-null mice, in
which the CD47 deficient red blood cells were rapidly cleared by
splenic macrophages (136). As macrophages abundantly express
the SIRP1a receptor, which binds to CD47, and depletion of
splenic macrophages protected CD47-/- red blood cells when
injected into wild-type mice, this suggests the CD47-SIRP1a axisFrontiers in Immunology | www.frontiersin.org 8represents a method of evasion of immune clearance and CD47
as a “marker of self” (136). CD47 is overexpressed in cancers
(137), and senescent cells upregulate expression of CD47 (138),
including in human renal proximal tubular epithelial cells. This
may allow cancers and senescent cells to appear as “self” to the
immune system and escape clearance. As previously mentioned,
senescent cells have roles in development (72), and it is possible
that their ability to upregulate CD47 is an example of
antagonistic pleiotropy (139), in which senescent cells need to
avoid clearance during development and therefore upregulate
CD47, an ability that becomes detrimental in later life as
senescent cells persist and generate SASP.
Other immune cells are affected by age. The number of
activated, CD56bright NK cells that produce cytokines decreases
with age in humans (>60 years) (140). In vitro studies have
shown that senescent cells are able to escape by NK cell
cytotoxicity by upregulation of HLA-E (MHC I) which can
bind inhibitory receptors on NK cells (41). In addition,
activating ligands for the NKG2D receptor such as MICA can
be cleaved from the surfaces of senescent cells by matrix
metalloproteases (MMPs) (141). These free MICA ligands are
able to bind to the NKG2A of NK cells and inhibit binding to
target cells, with a reversal of this evasion shown by a broad-
spectrum MMP inhibitor (141).THERAPEUTIC INTERVENTIONS TO
TACKLE DETRIMENTAL EFFECTS OF
CHRONIC SENESCENT CELLS
Macrophage Therapeutics
As macrophages have been shown to be involved in kidney
injury, with their removal at early timepoints appearing
beneficial (13, 122), controlled depletion of macrophages may
be of therapeutic interest. However, the methods used in these
mice studies may not effectively translate to humans, and there
may be off-target effects, depleting other macrophage
populations. This could be deleterious in some settings, for
instance if a patient was to suffer a myocardial event (142),
and could disrupt normal homeostasis of red blood cell turnover
by depletion of splenic macrophages (136).
Tailored genetic therapies are another possible option.
Macrophages that have had their SIRPa receptor knocked out
by CRISPr-Cas9, caused an increase of phagocytosis of human
osteosarcoma cells by a factor of 4 (143). This study did not
investigate phagocytic capacity of senescent cells, but logically as
the macrophages are the cells being edited, senescent cells would
also be more likely to be phagocytosed due to the lack of the
SIRPa on the macrophages. Again, this is limited by its proof-of-
principle in experimental settings, using human cell lines.
An alternative to time-consuming tailored healthcare, is the
administration of humanized anti-CD47 antibodies (144). This
study showed that the AO-176 antibody bound to human CD47,
resulting in increased tumor cell death. An advantage of this is
that the AO-176 antibody had minimal affinity for red blood
cells, a common drawback of previous CD47 antibodies (144).June 2021 | Volume 12 | Article 700790
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any anti-senescent properties is warranted.
Interventions to Improve Macrophage/
Senescent Cell Clearance
Klotho
The kidney accumulates senescent cells with age, with mouse
studies in which targeted depletion of senescent cells led to a
decrease in age-associated pathologies in the kidney (43).
Senescence is regulated internally by different mechanisms, one
of which is the Klotho gene. ICGN (‘Institute of Cancer
Research’- derived glomerulonephritis) mice transgenic for the
Klotho gene had an average survival of 70% compared to ICGN
controls (30%) (145). This overexpression of Klotho also led to a
decrease in senescence associated SA-b-Gal, an established
marker of senescence. Together, these indicate that Klotho
positively affects survival, possibly by reducing senescent
burden. Klotho knock-out mice have an increased number
senescent cells (146), and as human levels of Klotho decline
with CKD (147) it may be beneficial to increase soluble
KLOTHO levels in patients. This repression of accelerated
senescence, which is found with glomerulonephritis, preserves
renal function and improves survival (145).
Senolytics and Senomorphics
Senescent cells have been shown to accumulate in age and in
disease in both human and animal tissue and crucially, their
clearance in animal models is safe and has been shown to
improve health span (43) and organ function (39, 53). It has
become of therapeutic interest to remove senescent cells,
operating under the hypothesis that removal of chronically
senescent cells will have a positive impact on local andFrontiers in Immunology | www.frontiersin.org 9systemic tissues (Figure 3). Drugs that accomplish this are
called senolytics and treatments that target senescent cells are
called senotherapies.
Recent studies have focused on small molecular compounds
to inhibit the pro-survival mechanisms of senescent cells, such as
ABT-263 (Navitoclax) and ABT-737 (148) which inhibit Bcl2/w/
xL (39). ATB-263-induced elimination of senescent cells
improves prognosis after IRI injury in mice as seen by decrease
in fibrosis and ongoing injury, with increased levels of
regeneration and better kidney function (53). Human trials of
ABT-263 have revealed that the onset of thrombocytopenia
(abnormally low platelet counts) may limit the dose/timing of
ABT-263 administration to patients (149). Further research is
required to determine if ABT-263 can be used as a senolytic in
different settings, such as organ rejuvenation in transplants.
It has been shown that the senolytics, dasatinib and quercetin
(D+Q) can be safely used in humans (150, 151). D+Q have a
different target to ABT-263, and cause depletion of macrophages,
with early studies showing a decrease of macrophage number per
adipocyte by 28% (150). The control of senescent cell clearance
by pharmaceuticals proves crucial, as inhibition of acute
senescence present in wound healing (31, 32), could be
disruptive to natural wound-healing processes that animal
models/patients may be undergoing. This same study
demonstrated that common markers for senescent cells,
namely p16INK4a/p21CIP1 expression and b-galactosidase
activity at pH 6.0, were decreased post senolytic treatment, but
this can’t be attributed to Langerhans cell clearance or
macrophage recruitment (150).
It has been proposed that noncoding RNAs (ncRNAs) may
have a role in the regulation of SASP factors generated by
senescent cells (152). Exogenous administration of ncRNAsFIGURE 3 | Hypothesis of effects of senescent cell removal therapies on tissue function, with examples of each of different hallmarks and drivers listed for both
conditions. Graphs are not directly proportional as mitigating factors can alter the tissue functionality such as diet, exercise, disease.June 2021 | Volume 12 | Article 700790
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provide a complimentary approach to senescence therapeutics
such as senolytics and lifestyle adaptations.
Exposure to chemotherapeutic drugs such as Actinomycin D
(ActD) can induce senescence in human mesenchymal stem cells
(hMSCs) (153). Whilst the resident cells may be prevented from
becoming cancerous, the effect of the SASP-generating senescent
cells on the hMSC niche may be detrimental over time. Therefore,
it is important that be able to target the induced senescent cell
populations for removal, to give more tailored treatments.
Studies in which senescent cells were transplanted into
healthy young mice, showed an increase in mortality as a
result of senescent cell burden, which was subsequently
reversed by intermittent administration of dasatinib and
quercetin (154). This reduction of senescent cell burden has
also been replicated in humans with diabetic kidney disease,
however effects on mortality remain to be assessed (150).
Elimination of senescent cells relieved persistent physiological
dysfunctions including the secretion of frailty-related pro-
inflammatory cytokines, as demonstrated by human adiposeFrontiers in Immunology | www.frontiersin.org 10tissue explants (154). This and other methods are outlined in
Table 1, adapted with permission (160).
Lifestyle
Hall and colleagues showed that many p16INK4a and SA-b-gal
positive cells in the adipose tissue of mice may have been SAMs
(senescent associated macrophages), attracted by senescent cells,
and displaying pro-inflammatory (“M1”) phenotype (126) which
has been shown to create a sterile inflammatory environment
associated with obesity, as reviewed comprehensively (161). If
adiposity affects senescent cell numbers, this could indicate that
life-style choices (i.e. weight loss by calorie restriction and
exercise) may successfully reduce numbers of macrophages
secreting pro-inflammatory cytokines, by minimizing excess
adipose tissue in response to exercise, showing positive
feedback by reducing leptin (satiety hormone) (162) and
minimizing adipose tissue – which is reported to contain large
numbers of senescent cells (3) – and cause inflammation (126,
154). As briefly reviewed, by Xu and colleagues (163) pro-
inflammatory mediators can also be reduced by CR. This mayTABLE 1 | Experimental models of senescent cell deficiency/induction/depletion in the kidney and their effects on renal outcomes.
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↓ CD68+ macrophagesTransgenic and genetic knockout mice have been used to study the impact of 1) deficiencies in the induction of senescence or 2) depletion of established senescent cells. Several of these
models are summarized in this table, with description of the experimental model of renal disease used, the alteration in senescence induction employed and any alterations in renal disease
outcomes. TTD/TTD, trichothiodystrophy/trichothiodystrophy; GCV, ganciclovir; WT, wild-type; KO, knock-out; UUO, unilateral ureteric obstruction; IRI, ischemia-reperfusion injury; Tx,
Transplant; PAI-1, plasminogen activator inhibitor-1; GM-CSF, granulocyte macrophage colony-stimulating factor; IL-, Interleukin-; MMP-, Matrix Metalloprotease. Adapted with
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damage in response to transplantation procedures, caused by
ischemia-reperfusion injury, which may lead to an increase in
senescent burden and therefore premature ageing of the
transplant and surrounding tissues (164). However, as
previously mentioned this could lead to accelerated grey matter
atrophy (18), meaning cost-benefit analysis needs to be
considered for administration to patients.THERAPEUTICS – CONCLUSIONS
The presence of senescent cells may be the most relevant case of
the antagonistic pleiotropy theory of ageing (139), in that the key
genes involved in senescence are beneficial in early life,
promoting healthy embryogenesis (33) and rapid wound repair
whilst protecting from cancer formation/progression (35).
However, as senescent burden increases with age, SASP
generating cells comprise a larger proportion of non-
regenerating cell populations in tissues, negatively affecting
homeostasis (42, 126, 165). This would suggest that certain
therapeutic interventions, such as pharmaceutical treatment
(senolytics/senomorphics) or lifestyle changes [regular aerobic
exercise (3, 162)] may only show a significant impact when
administered to patients of a certain age, who have accumulated
enough senescent cell burden, and pharmaceutical interventions
may be preventative. Senescence has wide-reaching effects and
the elective administration of appropriate senolytics has the
potential to improve the quality of life for patients with
chronic conditions and age-associated morbidity, and further
clinical trials are warranted.CHALLENGES FOR FUTURE RESEARCH
INTO AGEING-ASSOCIATED FIBROSIS
Ageing is difficult to model in a translationally significant
manner using genetically close models, due to the marked
expense and timescale limitations of non-human primate
(NHP) models such as rhesus monkeys that live three to four
decades. Although uncommon, these studies have been
performed, pooling non-human primates (gorilla, rhesus
monkey, baboon and others) to identify conservation of certain
ageing phenotypes across species, such as arterial thickening
correlated to increased age (166). The trans-NIH GSIG summit
identified the induction of pathologies in young mice precludes
analysis of interactions with other aspects of ageing seen in
chronic diseases, requiring longer term studies to recapitulate the
ageing phenotype before pathology induction (4). To overcome
the limitations of relatively long-lived animals used for ageing,
other vertebrate models have been assessed for use, for example
the African turquoise killifish (Nothobranchius furzeri) has been
assessed as a model for aging against the “Hallmarks of Ageing”Frontiers in Immunology | www.frontiersin.org 11(1) and has begun to be genetically altered and separate lines
bred to provide a genetic toolkit to investigate ageing (167, 168).FINAL CONCLUSIONS
Senescent cells are attractive candidates as drivers of age-related
organ dysfunction. They are consistently seen in diseased and
older tissues when compared with healthy age-matched controls,
actively secreting pro-inflammatory and pro-fibrotic molecules
(90–92) capable of driving further (paracrine) senescence and
propagating on-going tissue damage (78, 125). This is potentially
because they secrete pro-inflammatory cytokines in the SASP
which modify the surrounding environment (169).
Macrophages contribute to clearance of senescent cells by
phagocytosis (73). This activity declines with age in multiple
organ systems (115), including the kidney, as macrophages
polarize from M1 to M2 in response to exogenous growth
factors (170), and can potentially become ‘senescent-associated’
(78, 125, 133) and possibly senescent themselves (129). This is
followed by a concurrent increase in fibrosis with age, which
negatively affects organ function.
New therapy strategies have been developed, both
pharmaceutical (39, 150) and lifestyle changes (126, 162) that
aim at reducing the burden of senescent cells and the SASP they
generate, and reducing inflammation, aimed at removing
blockades for macrophage polarity transitions essential for
response to injuries. This research is slowed by the feasibility
of ageing models currently utilized, however efforts by
researchers have brought new animals more relevant to ageing
research into mainstream use, as is the case with the African
Killifish (167, 168).
Ageing is a complex interaction of different physiological
responses that can be influenced by multiple factors from
genetics to the environment, but current research has and is
investigating these interactions and different factors for
therapeutic benefit in humans.AUTHOR CONTRIBUTIONS
RC: First author and primary writer. M-HD: Content
contributor. DF: Content contributor and editor. KJM: Content
contributor, editor, and last author. All authors contributed to
the article and approved the submitted version.FUNDING
RC is supported by the Wellcome Trust [108906/Z/15/Z]. M-HD
is supported by a MRC Clinical Training Research Fellowship
(CRTF) [MR/T008253/1]. DF is supported by Intermediate
Clinical Fellowship 1243 [WT100171MA] from the Wellcome
Trust. KJM is supported by a Chief Scientist Office/Kidney
Research UK Fellowship [CSO_PDF/2018/1].June 2021 | Volume 12 | Article 700790
Campbell et al. Ageing, Senescence and MacrophagesREFERENCES
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